{"id":"tdt067","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL822","moleculeType":"Small molecule","molecularWeight":"291.44"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TDT067 acts as a selective S1P1 receptor modulator, which is involved in the regulation of lymphocyte trafficking and immune responses. By modulating the S1P1 receptor, TDT067 aims to reduce inflammation and autoimmune responses.","oneSentence":"TDT067 is a small molecule that targets the S1P1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:51.193Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT07382427","phase":"PHASE2","title":"A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails","status":"NOT_YET_RECRUITING","sponsor":"Onyx Axiom","startDate":"2026-03","conditions":"Onychomycosis of Toenail","enrollment":200},{"nctId":"NCT07365423","phase":"PHASE2","title":"Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-05","conditions":"Recurrent Prostate Cancer","enrollment":42},{"nctId":"NCT07068256","phase":"NA","title":"Efficacy Comparison of Itraconazole Pulse Therapy and Terbinafine Therapy in Treatment of Tinea Capitis in Children.","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2025-04-01","conditions":"Tinea Capitis","enrollment":164},{"nctId":"NCT07242703","phase":"NA","title":"Efficacy of Ultraviolet B Phototherapy in the Management of Resistant and Relapsing Tinea Corporis and Tinea Cruris","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-12-01","conditions":"Fungal Resistance","enrollment":36},{"nctId":"NCT05667246","phase":"NA","title":"Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine","status":"ENROLLING_BY_INVITATION","sponsor":"Weill Medical College of Cornell University","startDate":"2024-07-25","conditions":"Terbinafine Adverse Reaction","enrollment":52},{"nctId":"NCT07152327","phase":"NA","title":"Terbinafine Hydrochloride for the Treatment of Otomycosis","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-10-01","conditions":"Otomycosis, Fungal Ear Infection","enrollment":50},{"nctId":"NCT07046988","phase":"","title":"Population Pharmacokinetics of Terbinafine in Children With Tinea Capitis","status":"RECRUITING","sponsor":"Shandong University","startDate":"2021-06-15","conditions":"Tinea Capitis","enrollment":60},{"nctId":"NCT06295328","phase":"PHASE1, PHASE2","title":"From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-04-13","conditions":"Chronic Hepatitis b","enrollment":36},{"nctId":"NCT00833586","phase":"PHASE1","title":"Terbinafine HCl 250 mg Tablet Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-01","conditions":"Healthy","enrollment":28},{"nctId":"NCT05279846","phase":"PHASE3","title":"A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Moberg Pharma AB","startDate":"2022-05-09","conditions":"Onychomycosis","enrollment":350},{"nctId":"NCT05049525","phase":"PHASE2","title":"Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease","status":"TERMINATED","sponsor":"Montreal Heart Institute","startDate":"2022-02-22","conditions":"Crohn's Disease, Inflammatory Bowel Diseases","enrollment":16},{"nctId":"NCT05482763","phase":"","title":"Mycosis Culture Collection From Dermatological Isolated","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rome Tor Vergata","startDate":"2022-07-20","conditions":"Onychomycosis, Resistant Infection, Nail Diseases","enrollment":200},{"nctId":"NCT06400056","phase":"PHASE1","title":"Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-05","conditions":"Fungal Resistance","enrollment":30},{"nctId":"NCT00647647","phase":"PHASE1","title":"Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-02","conditions":"Healthy","enrollment":36},{"nctId":"NCT00648713","phase":"PHASE1","title":"Fed Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® 250 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-02","conditions":"Healthy","enrollment":36},{"nctId":"NCT05119712","phase":"EARLY_PHASE1","title":"Terbinafine Treatment of Axial Spondyloarthropathy","status":"WITHDRAWN","sponsor":"Oregon Health and Science University","startDate":"2021-03-09","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis, Psoriatic Spondylitis","enrollment":""},{"nctId":"NCT05135910","phase":"PHASE2","title":"To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis","status":"UNKNOWN","sponsor":"Hallux, Inc.","startDate":"2022-01-13","conditions":"Onychomycosis of Toenail","enrollment":35},{"nctId":"NCT04188574","phase":"PHASE2","title":"A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail","status":"COMPLETED","sponsor":"Blueberry Therapeutics","startDate":"2021-03-22","conditions":"Distal Subungual Onychomycosis, Fungal Infection, Fungus, Nail","enrollment":111},{"nctId":"NCT05881980","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Terbinafine and Itraconazole","status":"UNKNOWN","sponsor":"Dhaka Medical College","startDate":"2023-05","conditions":"Tinea Corporis, Tinea Cruris, Tinea Faciei","enrollment":150},{"nctId":"NCT00833664","phase":"PHASE1","title":"Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-01","conditions":"Healthy","enrollment":22},{"nctId":"NCT05578950","phase":"PHASE1","title":"Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis","status":"COMPLETED","sponsor":"Combined Military Hospital Abbottabad","startDate":"2022-03-01","conditions":"Onychomycosis","enrollment":100},{"nctId":"NCT02366884","phase":"PHASE2","title":"Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)","status":"UNKNOWN","sponsor":"Dr. Frank Arguello Cancer Clinic","startDate":"2011-07-26","conditions":"Neoplasms","enrollment":250},{"nctId":"NCT04880980","phase":"PHASE3","title":"Comparison of Efficacy of Double Dose Oral Terbinafine Vs Itraconazole in Treatment of Dermatophyte Infections of Skin.","status":"COMPLETED","sponsor":"Pak Emirates Military Hospital","startDate":"2021-03-15","conditions":"Dermatophyte Infection, Terbinafine Adverse Reaction, Itraconazole Adverse Reaction","enrollment":120},{"nctId":"NCT05128916","phase":"PHASE3","title":"Efficacy of Intralesional PRP in Treatment of Onychomycosis","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2021-12-01","conditions":"Platelet Rich Plasma","enrollment":75},{"nctId":"NCT02606032","phase":"PHASE2","title":"Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2016-05","conditions":"Ulcerative Colitis","enrollment":75},{"nctId":"NCT02859519","phase":"PHASE3","title":"A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)","status":"COMPLETED","sponsor":"Moberg Pharma AB","startDate":"2016-10","conditions":"Distal Subungual Onychomycosis","enrollment":365},{"nctId":"NCT03999437","phase":"PHASE2","title":"SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS","status":"UNKNOWN","sponsor":"United Laboratories","startDate":"2019-01-02","conditions":"Tinea Pedis","enrollment":42},{"nctId":"NCT03471455","phase":"PHASE2","title":"Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2018-04","conditions":"Tinea","enrollment":100},{"nctId":"NCT00602342","phase":"NA","title":"Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2004-03","conditions":"Onychomycosis","enrollment":30},{"nctId":"NCT00602251","phase":"NA","title":"Bioequivalency Study of Terbinafine Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2004-03","conditions":"Onychomycosis","enrollment":30},{"nctId":"NCT03094468","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis","status":"WITHDRAWN","sponsor":"Polichem S.A.","startDate":"2017-05","conditions":"Onychomycosis of Toenail","enrollment":""},{"nctId":"NCT03135912","phase":"PHASE2","title":"Three-Arm Trial of Novel Treatment for Tinea Pedis","status":"COMPLETED","sponsor":"South End Skin Care","startDate":"2017-01-03","conditions":"Tinea Pedis","enrollment":90},{"nctId":"NCT01772212","phase":"PHASE1","title":"Bioequivalence Study for Terbinafine 250 mg","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-24","conditions":"Mycoses","enrollment":30},{"nctId":"NCT03171584","phase":"PHASE3","title":"Antifungal Drugs in Treatment of Onychomycosis","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-07-01","conditions":"Antifungal Drugs in Onychomycosis","enrollment":60},{"nctId":"NCT00117767","phase":"PHASE3","title":"Terbinafine Compared to Griseofulvin in Children With Tinea Capitis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-06","conditions":"Tinea Capitis","enrollment":720},{"nctId":"NCT01920178","phase":"NA","title":"Evaluation Study for the Efficacy and Safety of PinPointe FootLaser in Treatment for Onychomycosis","status":"TERMINATED","sponsor":"Cambridge Health Alliance","startDate":"2013-04","conditions":"Onychomycosis of Toenails","enrollment":7},{"nctId":"NCT00491764","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Onychomycosis","enrollment":218},{"nctId":"NCT02019446","phase":"NA","title":"Laser Treatment for Onychomycosis in Diabetes","status":"UNKNOWN","sponsor":"BCDiabetes.Ca","startDate":"2018-07","conditions":"Diabetes Mellitus, Type 2, Onychomycosis","enrollment":60},{"nctId":"NCT01851590","phase":"PHASE4","title":"Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2013-10","conditions":"Onychomycosis","enrollment":129},{"nctId":"NCT01400594","phase":"PHASE2","title":"Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail","status":"COMPLETED","sponsor":"Hisamitsu Pharmaceutical Co., Inc.","startDate":"2011-07","conditions":"Onychomycosis","enrollment":182},{"nctId":"NCT01013909","phase":"PHASE2","title":"Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-12","conditions":"Tinea Pedis","enrollment":220},{"nctId":"NCT01584765","phase":"","title":"Rechallenge, Potential Drug Induced Liver Injury (Kaiser)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02","conditions":"Drug-induced Liver Injury","enrollment":1},{"nctId":"NCT01433107","phase":"PHASE3","title":"Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-08","conditions":"Tinea Pedis","enrollment":290},{"nctId":"NCT01790165","phase":"PHASE2","title":"TDT 067 Open Label Multi-Dose Onychomycosis Study","status":"COMPLETED","sponsor":"Celtic Pharma Development Services","startDate":"2009-12","conditions":"Onychomycosis","enrollment":27},{"nctId":"NCT01080079","phase":"PHASE2","title":"Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis","status":"COMPLETED","sponsor":"Nitric BioTherapeutics, Inc","startDate":"2010-05","conditions":"Onychomycosis","enrollment":168},{"nctId":"NCT01484145","phase":"PHASE2","title":"Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail","status":"COMPLETED","sponsor":"Nitric BioTherapeutics, Inc","startDate":"2011-12","conditions":"Onychomycosis","enrollment":25},{"nctId":"NCT01145807","phase":"PHASE3","title":"TDT 067 Onychomycosis Study","status":"UNKNOWN","sponsor":"Celtic Pharma Development Services","startDate":"2010-04","conditions":"Onychomycosis","enrollment":738},{"nctId":"NCT01615913","phase":"PHASE1","title":"Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole","status":"UNKNOWN","sponsor":"Taiwan Biotech Co., Ltd.","startDate":"2012-04","conditions":"Onychomycosis","enrollment":18},{"nctId":"NCT00443898","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Onychomycosis","enrollment":518},{"nctId":"NCT01286701","phase":"PHASE1","title":"Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2002-01","conditions":"Healthy","enrollment":18},{"nctId":"NCT01286688","phase":"PHASE1","title":"Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2002-01","conditions":"Fasting","enrollment":36},{"nctId":"NCT00459537","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Onychomycosis","enrollment":1029},{"nctId":"NCT00443820","phase":"PHASE3","title":"Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Onychomycosis","enrollment":526},{"nctId":"NCT00768768","phase":"PHASE1","title":"Iontophoretic Application of Terbinafine Gel to the Large Toe Nail","status":"COMPLETED","sponsor":"Transport Pharmaceuticals","startDate":"2008-10","conditions":"Onychomycosis","enrollment":40},{"nctId":"NCT00691184","phase":"PHASE1","title":"Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis","status":"COMPLETED","sponsor":"NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)","startDate":"2005-02","conditions":"Onychomycosis/Onycholysis and Tinea Pedis","enrollment":56},{"nctId":"NCT00253305","phase":"PHASE2","title":"Topical Gel Anti-Fungal Agent for Tinea Unguium","status":"COMPLETED","sponsor":"MediQuest Therapeutics","startDate":"2005-09","conditions":"Onychomycosis","enrollment":75},{"nctId":"NCT00117754","phase":"PHASE3","title":"Terbinafine Compared to Griseofulvin in Children With Tinea Capitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-07","conditions":"Tinea Capitis","enrollment":720},{"nctId":"NCT00002394","phase":"NA","title":"Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment","status":"COMPLETED","sponsor":"Novartis","startDate":"","conditions":"Candidiasis, Oral, HIV Infections","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TDT067","genericName":"TDT067","companyName":"Celtic Pharma Development Services","companyId":"celtic-pharma-development-services","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TDT067 is a small molecule that inhibits the enzyme squalene monooxygenase. It is being studied in clinical trials for various conditions, including neoplasms, drug-induced liver injury, and mycoses, among others.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}